Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.

[1]  Mark M. Melendez,et al.  Influence of Age on the Association of Retinol‐binding Protein 4 With Metabolic Syndrome , 2008, Obesity.

[2]  M. Nagai,et al.  Development of a new method for estimating visceral fat area with multi-frequency bioelectrical impedance. , 2008, The Tohoku journal of experimental medicine.

[3]  A. Wierzbicki,et al.  HIV lipodystrophy and its metabolic consequences: implications for clinical practice , 2008, Current medical research and opinion.

[4]  G. Brinkworth,et al.  Good agreement between bioelectrical impedance and dual-energy X-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women. , 2007, Clinical nutrition.

[5]  Xu Lin,et al.  Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  P. Scifo,et al.  Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  J. Shim,et al.  Visceral Adiposity Is Associated with Serum Retinol Binding Protein‐4 Levels in Healthy Women , 2007, Obesity.

[8]  P. Lepper,et al.  Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease , 2007, Diabetologia.

[9]  M. Fasshauer,et al.  Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. , 2007, Cell metabolism.

[10]  M. Wolzt,et al.  Effect of Rosiglitazone on Visfatin and Retinol‐Binding Protein‐4 Plasma Concentrations in HIV‐Positive Patients , 2007, Clinical pharmacology and therapeutics.

[11]  K. Park,et al.  Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes , 2007, Diabetes Care.

[12]  Yoshihiro Mukuta,et al.  Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. , 2006, American journal of hypertension.

[13]  M. Wolzt,et al.  Impact of antiretroviral therapy on visfatin and retinol‐binding protein 4 in HIV‐infected subjects , 2006, European journal of clinical investigation.

[14]  M. Martínez-Larrad,et al.  Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. , 2006, Metabolism: clinical and experimental.

[15]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[16]  M. Lazar,et al.  HIV Protease Inhibitor‐Specific Alterations in Human Adipocyte Differentiation and Metabolism , 2006, Obesity.

[17]  G. Bárbaro.  Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. , 2006, American journal of therapeutics.

[18]  S. R. Ferreira,et al.  The new adipose tissue and adipocytokines. , 2006, Current diabetes reviews.

[19]  J. Chan,et al.  Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  R. Weber,et al.  Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study , 2005, Antiviral therapy.

[21]  S. Grinspoon,et al.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[22]  P. Hruz,et al.  A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity* , 2004, Journal of Biological Chemistry.

[23]  S. Demura,et al.  Percentage of total body fat as estimated by three automatic bioelectrical impedance analyzers. , 2004, Journal of physiological anthropology and applied human science.

[24]  J. Choi,et al.  Bone mineral density correlates strongly with basal metabolic rate in postmenopausal women. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[25]  C. Mantzoros,et al.  Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  A. Garg,et al.  Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .

[27]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[28]  D. Devost,et al.  HIV-protease inhibitors alter retinoic acid synthesis , 2001, AIDS.

[29]  S. Ajzen,et al.  Ultrasonography for the Evaluation of Visceral Fat and Cardiovascular Risk , 2001, Hypertension.

[30]  J. Buring,et al.  Abdominal and total adiposity and risk of coronary heart disease in men , 2001, International Journal of Obesity.

[31]  D A Follmann,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .

[32]  P. Gouras,et al.  Impaired retinal function and vitamin A availability in mice lacking retinol‐binding protein , 1999, The EMBO journal.

[33]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[34]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[35]  R. Suzuki,et al.  Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. , 1993, The American journal of medicine.

[36]  M. Zamboni,et al.  Total and intra-abdominal fat measurements by ultrasound and computerized tomography. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[37]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.

[38]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[39]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[40]  이지원,et al.  Visceral Adiposity Is Associated with Serum Retinol Binding Protein-4 Levels in Healthy Women , 2007 .